Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
N/A
1(25.0%)
Phase 1
1(25.0%)
4Total
Phase 2(2)
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06949800Phase 2Not Yet Recruiting

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

Role: collaborator

NCT05090267Not ApplicableRecruiting

The Path Study: Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study

Role: collaborator

NCT05938465Phase 1Recruiting

Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)

Role: lead

NCT02706717Phase 2Completed

Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers

Role: collaborator

All 4 trials loaded